{"schema_version":"secwatch.filing_event.v1","accession":"0001321732-26-000036","form_type":"8-K","ticker":"PEN","cik":"0001321732","company_name":"Penumbra Inc","filed_at":"2026-07-30T20:14:23+00:00","discovered_at":"2026-07-30T20:15:09.240211+00:00","generated_at":"2026-07-30T20:15:23.436073+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Penumbra Q2 revenue $390M (+14.9% YoY); net income $34.8M; pending BSX acquisition","bullets":["Revenue $390.0M, up 14.9% YoY; global thrombectomy $259.0M (+12.5%), embolization & access $131.1M (+20.0%).","Gross profit margin 67.9%, up 1.9 percentage points YoY.","Income from operations $41.0M; net income $34.8M.","Operating expenses include $6.9M acquisition-related costs for pending Boston Scientific acquisition.","Company will not provide FY2026 guidance due to pending acquisition."],"urls":{"canonical":"https://secwatch.observer/filing/0001321732-26-000036","json":"https://secwatch.observer/filing/0001321732-26-000036.json","markdown":"https://secwatch.observer/filing/0001321732-26-000036.md","text":"https://secwatch.observer/filing/0001321732-26-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321732/000132173226000036/0001321732-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321732/000132173226000036/pen-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:15:23.436073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}